Aeterna Zentaris Reports First Quarter 2024 Financial Results
Aeterna Zentaris (NASDAQ: AEZS) reported its Q1 2024 financial results, highlighting a cash position of $29.5 million as of March 31, 2024. The company reported a net loss of $5.8 million, compared to a $4.3 million loss in Q1 2023. This increased loss is attributed to a $2.1 million revenue drop and a $1.2 million rise in selling, general, and administrative expenses, mostly due to merger-related costs. The company successfully completed recruitment for its DETECT-trial, with results expected in Q3 2024. The merger with Ceapro Inc. is anticipated to close in Q2 2024.
- Aeterna Zentaris reported a strong cash position of $29.5 million as of Q1 2024.
- The company completed recruitment for its DETECT-trial, with top-line data expected by Q3 2024.
- The anticipated merger with Ceapro Inc. is expected to close in Q2 2024, potentially increasing business synergies.
- Aeterna reported a net loss of $5.8 million for Q1 2024, up from $4.3 million in Q1 2023.
- Revenue for Q1 2024 decreased by $2.1 million due to the termination of an agreement with Novo Nordisk Healthcare.
- Selling, general, and administrative expenses increased by $1.2 million, primarily due to non-recurring merger-related costs.
Insights
Financial Performance Analysis: Aeterna Zentaris ended the first quarter of 2024 with
The termination of the agreement with Novo Nordisk significantly impacted revenue streams. This highlights the company's reliance on partnership agreements for revenue. The decrease in research and development expenses by
For retail investors, the major points of interest are the company's robust cash reserves and the handling of increased expenses amid declining revenues. Monitoring future financial reports will be essential to gauge the long-term impact of these changes and the sustainability of the company’s financial health.
Market Position and Strategic Moves: The completion of the DETECT-trial and the upcoming merger with Ceapro Inc. are pivotal events. The successful completion of the DETECT-trial, expected by the third quarter of 2024, could potentially open new revenue streams and strengthen Aeterna’s market position. Clinical trials are a critical component in the pharmaceutical industry, as positive results can significantly boost a company's value and market perception.
The merger with Ceapro Inc. is a strategic move towards diversifying Aeterna’s portfolio and expanding its market reach. Mergers of equals are particularly interesting as they can lead to enhanced capabilities without the substantial cash outlays typical of acquisitions. The expected synergies from this merger, including shared technology and combined expertise, could result in improved efficiencies and product offerings. However, mergers also come with integration risks and potential initial disruptions.
For retail investors, understanding the potential long-term benefits of the DETECT-trial and the merger is crucial. While the immediate financial results show a decline, these strategic initiatives could pave the way for future growth and stability.
- Company ended the quarter with
$29.5 million in cash - DETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third quarter of 2024
- All-stock merger of equals transaction with Ceapro Inc. expected to close in the second quarter of 2024
TORONTO, ONTARIO, May 14, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the quarter ended March 31, 2024.
Mr. Giuliano La Fratta, Chief Financial Officer of Aeterna commented, “This year remains exciting for Aeterna. Our cash position remains strong and we continue to be on track to complete both the DETECT-trial and the previously announced merger with Ceapro Inc. (“Ceapro”) in the second quarter.”
Summary of First Quarter 2024 Financial Results
All amounts are in U.S. dollars.
Cash and cash equivalents
The Company had
Results of operations for the three-month period ended March 31, 2024
For the three-month period ended March 31, 2024, we reported a net loss of
Revenues
- Our total revenue for the three-month period ended March 31, 2024, decreased by
$2.1 million . The decrease was due to the termination of the Company’s amended agreement with Novo Nordisk Healthcare in May 2023 and as a result, no license fee or development services revenue was recognized in Q1, 2024.
Operating Expenses
- Our total operating expenses for the three-month period ended March 31, 2024, was
$6.1 million as compared with$6.3 million for the same period in 2023, representing a decrease of$0.2 million . This decrease was primarily from a$1.4 million decrease in research and development expenses offset by a$1.2 million increase in the selling, general and administrative expenses.
Consolidated Financial Statements and Management's Discussion and Analysis
For reference, the Management's Discussion and Analysis of Financial Condition and Results of Operations for the first quarter 2024, as well as the Company's consolidated financial statements as of March 31, 2024, will be available on the Company's website (www.zentaris.com) in the Investors section or at the Company's SEDAR+ and EDGAR profiles at www.sedarplus.ca and www.sec.gov, respectively.
About Macimorelin (Macrilen®; GHRYVELIN™)
Macimorelin, an oral drug used for the diagnosis of adult growth hormone deficiency (AGHD) is approved for marketing under the brand name GHRYVELIN™ in the European Economic Area and Macrilen® in the United States. In addition, Aeterna Zentaris is currently conducting the Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency (CGHD).
Macimorelin (Macrilen®; GHRYVELIN™), a ghrelin receptor agonist, is an orally active peptidomimetic molecule that stimulates the secretion of growth hormone from the pituitary gland. Stimulated growth hormone levels are measured in blood samples taken after oral administration of macimorelin for the assessment of AGHD. Approval of macimorelin for use in adult was granted by the FDA in 2017 and by the EMEA in 2019, based on Phase III data showing that oral macimorelin provides accuracy comparable to that of standard insulin tolerance testing (ITT), but has a more favorable safety profile compared to ITT. Oral macimorelin also reduces false positive test results, helping to avoid unnecessary treatment of patients.
About Aeterna Zentaris Inc.
Aeterna is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. Aeterna's lead product, macimorelin (Macrilen; Ghryvelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Aeterna is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.
Aeterna is also dedicated to the development of its therapeutic assets and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease).
For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains statements that may constitute forward-looking statements within the meaning of U.S. and Canadian securities legislation and regulations, and such statements are made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements are frequently, but not always, identified by words such as "expects," "aiming", "anticipates," "believes," "intends," "potential," "possible," and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainty and assumptions, known and unknown, many of which are beyond our control.
Forward-looking statements in this press release include, but are not limited to, those relating to Aeterna's expectations regarding: the strength of its cash position, the completion of the DETECT-trial, the ability of Aeterna and Ceapro to complete the merger transaction with Ceapro (the “Transaction”) on the terms described herein, or at all, and and the timing of the closing of the Transaction.
Forward-looking statements involve known and unknown risks and uncertainties, and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks and uncertainties include, among others, our reliance on the success of the DETECT clinical trial in the European Union and U.S. for Macrilen™ (macimorelin) in CGHD; results from our ongoing or planned pre-clinical studies and our DETECT clinical trial under development may not be successful or may not support advancing the product further in pre-clinical studies, to human clinical trials or regulatory approval; our ability to raise capital and obtain financing to continue our currently planned operations; our now heavy dependence on the success of Macrilen™ (macimorelin) and related out-licensing arrangements and the continued availability of funds and resources to successfully commercialize the product; the global instability due to the global pandemic of COVID-19 and the war in the Ukraine, and their unknown potential effect on our planned operations; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our ability to continue to list our common shares on the NASDAQ; and the availability and timing of required stock exchange, regulatory and other approvals for the completion of the transaction with Ceapro. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties, including those risks discussed under the caption “Risk Factors” in our Annual Report on Form 20-F, which is available on the Company’s EDGAR profile at www.sec.gov. Given the uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.
Information Concerning the Registration Statement
Aeterna filed a Registration Statement on Form F-1 (including a prospectus) (File No. 333-277115) (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) for the issuance of common share purchase warrants and common shares issuable upon exercise thereof in connection with the Transaction, but it has not yet become effective. The common share purchase warrants and common shares issuable upon exercise thereof may not be sold nor may offers to buy them be accepted prior to the time the Registration Statement becomes effective. Before you invest in any Aeterna common shares, you should read the prospectus in the Registration Statement and the other documents incorporated by reference therein for more complete information about Aeterna, Ceapro, the Transaction and the common share purchase warrant offering.
You may get copies of the Registration Statement for free by visiting EDGAR on the SEC website at www.sec.gov or at SEDAR+ at www.sedarplus.ca. Alternatively, you may obtain copies of them by contacting Aeterna’s investor contact at the details provided below. Other than as noted above, none of the securities to be issued pursuant to or in connection with the Transaction have been or will be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. state securities laws, and such securities are anticipated to be issued in reliance on the exemption from the registration requirements of the U.S. Securities Act provided by Section 3(a)(10) thereof and similar exemptions under applicable state securities laws.
No Offer or Solicitation
This news release and the information contained herein are not, and do not, constitute an offer to sell any securities or a solicitation of an offer to buy any securities in the United States or any other state or jurisdiction, nor shall any securities of Aeterna be offered or sold in any jurisdiction in which such an offer, solicitation or sale would be unlawful. Neither the SEC nor any state securities commission has approved or disapproved of the transactions described herein or determined if this communication is truthful or complete. Any representation to the contrary is a criminal offense.
You should not construe the contents of this communication as legal, tax, accounting or investment advice or a recommendation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein.
No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this release.
Investor Contact:
Jenene Thomas
JTC Team
T : +1 (833) 475-8247
E: aezs@jtcir.com
FAQ
What was Aeterna Zentaris' cash position in Q1 2024?
What were Aeterna Zentaris' Q1 2024 financial results?
What is the status of Aeterna Zentaris' DETECT-trial?
When is the Aeterna Zentaris and Ceapro Inc. merger expected to close?
Why did Aeterna Zentaris' revenue decrease in Q1 2024?
